Risk Profiles
Compound-specific risk profiles covering side effects, contraindications, and monitoring recommendations for each peptide in the library.
Not Medical Advice
These profiles are educational summaries. Side effect frequency and severity vary by individual. Your provider should assess your personal risk factors before prescribing any compound.
Risk Level Guide
Low — generally well-toleratedModerate — common side effects, monitoring requiredModerate-High — significant monitoring and precautions needed
GLP-1 Receptor Agonists
Semaglutide
ModerateCommon Side Effects
- •Nausea (20-44%)
- •Vomiting (5-24%)
- •Diarrhea (8-30%)
- •Constipation (5-24%)
- •Injection site reactions
Serious Risks
- •Pancreatitis (rare)
- •Gallbladder disease
- •Thyroid C-cell tumors (animal data; boxed warning)
- •Hypoglycemia when combined with insulin or sulfonylureas
Contraindications
- •Personal or family history of medullary thyroid carcinoma (MTC)
- •Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- •History of pancreatitis
Monitoring Requirements
- •Weight and BMI at each visit
- •HbA1c every 3 months if diabetic
- •Lipase/amylase if GI symptoms worsen
- •Thyroid function baseline and annually
Tirzepatide
ModerateCommon Side Effects
- •Nausea (12-33%)
- •Diarrhea (12-23%)
- •Decreased appetite
- •Vomiting (5-9%)
- •Dyspepsia
Serious Risks
- •Pancreatitis (rare)
- •Gallbladder disease
- •Thyroid C-cell tumors (boxed warning, animal data)
- •Severe GI events including ileus
Contraindications
- •Personal or family history of MTC
- •MEN 2 syndrome
- •History of severe pancreatitis
Monitoring Requirements
- •Weight and BMI at each visit
- •HbA1c every 3 months if diabetic
- •Lipase/amylase with GI complaints
- •Renal function (dehydration risk from GI side effects)
Growth Hormone Secretagogues
MK-677 (Ibutamoren)
Moderate-HighCommon Side Effects
- •Increased appetite
- •Water retention and bloating
- •Joint pain
- •Elevated blood glucose
- •Lethargy
Serious Risks
- •Insulin resistance and glucose intolerance
- •Worsening of existing diabetes
- •Potential tumor growth promotion (GH/IGF-1 axis)
- •Carpal tunnel syndrome
Contraindications
- •Active malignancy
- •Uncontrolled diabetes
- •Pituitary tumors
- •History of carpal tunnel syndrome
Monitoring Requirements
- •Fasting glucose and HbA1c every 3 months
- •IGF-1 levels every 3-6 months
- •Fasting insulin levels
- •Blood pressure monitoring
CJC-1295 / Ipamorelin
Low-ModerateCommon Side Effects
- •Injection site reactions
- •Water retention
- •Tingling or numbness in extremities
- •Headache
- •Flushing
Serious Risks
- •Potential tumor growth promotion (theoretical)
- •Carpal tunnel symptoms at high doses
- •Glucose intolerance
Contraindications
- •Active malignancy
- •Pituitary disorders
- •Pregnancy or breastfeeding
Monitoring Requirements
- •IGF-1 levels every 3-6 months
- •Fasting glucose
- •General metabolic panel
Tissue Repair Peptides
BPC-157
Low (Limited Human Data)Common Side Effects
- •Injection site discomfort
- •Nausea (oral form)
- •Dizziness (rare)
- •Headache (rare)
Serious Risks
- •Limited human clinical trial data
- •Unknown long-term effects
- •Theoretical concern for tumor angiogenesis (promotes blood vessel growth)
Contraindications
- •Active malignancy (theoretical, due to angiogenic properties)
- •Pregnancy or breastfeeding
Monitoring Requirements
- •General health monitoring
- •No established monitoring protocol due to lack of clinical trials
TB-500 (Thymosin Beta-4)
Low (Limited Human Data)Common Side Effects
- •Injection site reactions
- •Headache
- •Lethargy
- •Temporary lightheadedness
Serious Risks
- •Limited human safety data
- •Theoretical tumor growth promotion
- •Unknown interactions with immune-modulating drugs
Contraindications
- •Active malignancy
- •Pregnancy or breastfeeding
Monitoring Requirements
- •General health monitoring
- •CBC if used long-term
Hormone Optimization
Testosterone (TRT)
ModerateCommon Side Effects
- •Acne
- •Hair thinning or loss
- •Increased hematocrit
- •Testicular atrophy
- •Mood changes
- •Fluid retention
Serious Risks
- •Polycythemia (elevated red blood cells) — stroke and clot risk
- •Cardiovascular events (FDA warning)
- •Liver toxicity (oral forms)
- •Sleep apnea worsening
- •Infertility during use
Contraindications
- •Prostate or breast cancer
- •Hematocrit > 54%
- •Severe untreated sleep apnea
- •Uncontrolled heart failure
- •Desire for fertility (without adjunct HCG)
Monitoring Requirements
- •CBC with hematocrit every 3-6 months
- •PSA and digital rectal exam annually
- •Comprehensive metabolic panel
- •Lipid panel every 6-12 months
- •Total and free testosterone levels
- •Estradiol levels
Enclomiphene
Low-ModerateCommon Side Effects
- •Visual disturbances (floaters, blurring)
- •Headache
- •Nausea
- •Hot flashes
- •Mood changes
Serious Risks
- •Visual changes (discontinue if persistent)
- •Ovarian hyperstimulation (in females)
- •Thromboembolic events (rare)
Contraindications
- •Liver disease
- •Undiagnosed abnormal uterine bleeding
- •Ovarian cysts (females)
- •Pituitary tumors
Monitoring Requirements
- •LH, FSH, total testosterone every 6-8 weeks initially
- •Liver function tests
- •Visual symptom assessment
- •Semen analysis if fertility is a goal
Missing a Compound?
We are actively expanding risk profiles for all compounds in the library. If you need safety information on a compound not listed here, consult your prescribing provider or pharmacist.